PMID- 32983145
OWN - NLM
STAT- MEDLINE
DCOM- 20210422
LR  - 20210422
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem 
      Cell Transplantation.
PG  - 2022
LID - 10.3389/fimmu.2020.02022 [doi]
LID - 2022
AB  - Natural killer (NK) cells play a significant role in immune tolerance and immune 
      surveillance. Killer immunoglobin-like receptors (KIRs), which recognize human 
      leukocyte antigen (HLA) class I molecules, are particularly important for NK cell 
      functions. Previous studies have suggested that, in the setting of hematopoietic 
      stem cell transplantation (HSCT), alloreactive NK cells from the donor could 
      efficiently eliminate recipient tumor cells and the residual immune cells. 
      Subsequently, several clinical models were established to determine the optimal 
      donors who would exhibit a graft-vs. -leukemia (GVL) effect without developing 
      graft-vs. -host disease (GVHD). In addition, hypotheses about specific beneficial 
      receptor-ligand pairs and KIR genes have been raised and the favorable effects of 
      alloreactive NK cells are being investigated. Moreover, with a deeper 
      understanding of the process of NK cell reconstitution post-HSCT, new factors 
      involved in this process and the defects of previous models have been observed. 
      In this review, we summarize the most relevant literatures about the impact of NK 
      cell alloreactivity on transplant outcomes and the factors affecting NK cell 
      reconstitution.
CI  - Copyright (c) 2020 Gao, Ye, Gao, Huang and Zhao.
FAU - Gao, Fei
AU  - Gao F
AD  - Bone Marrow Transplantation Center, The First Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
AD  - Institute of Hematology, Zhejiang University, Hangzhou, China.
AD  - Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China.
FAU - Ye, Yishan
AU  - Ye Y
AD  - Bone Marrow Transplantation Center, The First Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
AD  - Institute of Hematology, Zhejiang University, Hangzhou, China.
AD  - Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China.
FAU - Gao, Yang
AU  - Gao Y
AD  - Bone Marrow Transplantation Center, The First Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
AD  - Institute of Hematology, Zhejiang University, Hangzhou, China.
AD  - Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China.
FAU - Huang, He
AU  - Huang H
AD  - Bone Marrow Transplantation Center, The First Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
AD  - Institute of Hematology, Zhejiang University, Hangzhou, China.
AD  - Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China.
FAU - Zhao, Yanmin
AU  - Zhao Y
AD  - Bone Marrow Transplantation Center, The First Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
AD  - Institute of Hematology, Zhejiang University, Hangzhou, China.
AD  - Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200902
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Alleles
MH  - Animals
MH  - Biomarkers
MH  - Graft Survival
MH  - Graft vs Host Disease/etiology/metabolism
MH  - HLA Antigens/genetics/immunology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/methods
MH  - Humans
MH  - *Immune Reconstitution
MH  - Killer Cells, Natural/*immunology/*metabolism
MH  - Ligands
MH  - Protein Binding
MH  - Receptors, KIR/genetics/*metabolism
MH  - Treatment Outcome
PMC - PMC7493622
OTO - NOTNLM
OT  - GVHD
OT  - KIR
OT  - NK cell reconstitution
OT  - hematopoietic stem cell transplantation
OT  - infection
OT  - relapse
EDAT- 2020/09/29 06:00
MHDA- 2021/04/23 06:00
PMCR- 2020/01/01
CRDT- 2020/09/28 05:41
PHST- 2020/05/27 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/09/28 05:41 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.02022 [doi]
PST - epublish
SO  - Front Immunol. 2020 Sep 2;11:2022. doi: 10.3389/fimmu.2020.02022. eCollection 
      2020.